← Leaderboards
James Lee
Id4pharma, Llc
$2,306,840
Attributed
$2,306,840
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$2,306,840 · 1
By mechanism
R44$2,306,840 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Drug Resistance”
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,448,823
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$30,845,607
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Ryan Cirz · Revagenix, Inc.$22,711,751
- Bruce Blough · Research Triangle Institute$19,637,160
Research focus
Drug ResistanceExperimental StudyDosageDrug DiscoveryDrug TargetingExhibitsBiotechnologyAgreementBoneDrug DesignBindingBortezomibBiological AvailabilityCell PhysiologyCellsChemical PropertyBiotinChemistryClinical DataClinical InvestigationAntineoplastic AgentsAdaptor Signaling ProteinBone MarrowFda Approved
Grant awards (4)
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$1,000,000
R44 · FY2019 · CA · contact PI
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$1,000,000
R44 · FY2018 · CA · contact PI
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$6,840
R44 · FY2018 · CA · contact PI
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease$300,000
R44 · FY2017 · CA · contact PI